Navigation Links
Frost and Sullivan Picks Epinex for Diabetes Research Award
Date:3/17/2009

IRVINE, Calif., March 17 /PRNewswire/ -- Frost & Sullivan will present the 2009 Excellence in Research Award in the Global Diabetes Diagnostics Market to Epinex for developing the G1A(TM) Rapid Diabetes Monitoring Index Test. Frost & Sullivan is an internationally renowned market research and business growth consulting firm with over forty-five years of history in the global marketplace. The award ceremony will be held at the 'Excellence in Medical Technologies & Life Sciences Banquet' in San Francisco on Wednesday, March 18, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090317/LA85174LOGO)

This award recognizes research and development programs whose "disruptive research" has the potential to revolutionize the marketplace and influence the creation and adoption of new technologies. "Award recipients are pioneers in the industry," explains Frost & Sullivan's Director of Healthcare Research Monali Patel Shastry.

Frost & Sullivan believes that Epinex's revolutionary approach to diabetes monitoring could make a significant contribution to the diagnostic industry. According to their report, the G1A(TM) test uses a "superior but previously unavailable marker (glycated albumin)... to create a breakthrough in the diabetes diagnostics market." Frost & Sullivan expects Epinex to "expand globally as it continues its development of innovative cost-effective diagnostic tools."

The G1A(TM) test fulfills an unmet need in diabetes monitoring. Recent research has shown that glycated albumin is a better marker for diabetics on hemodialysis, diabetics with red blood cell disorders, and women with gestational diabetes. The G1A(TM) test is a monthly at-home or point-of-care test that uses glycated albumin to measure the damage caused by excess sugar. It encourages preventive care and positive lifestyle changes by introducing a monthly diabetes management paradigm.

The Asheville Project has already demonstrated the health benefit and cost effectiveness of monthly diabetes monitoring by significantly improving patient health and reducing direct medical costs over a period of five years. Similar projects are now underway across the country, including a corporate wellness program developed jointly by Epinex research associate Henna Zaidi and the American Diabetes Association office in Orange County, Southern California.

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A(TM) test at www.epinex.com.

    Contact:
    Jacqueline Morales
    Public Relations
    Epinex Diagnostics, Inc.
    Phone 949-660-7770, ext. 106
    jacqueline@epinex.com


'/>"/>
SOURCE Epinex Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Northern Kentucky - Cincinnati, Ohio (PRWEB) , ... ... ... leader in the production of miniature, folded, pharmaceutical inserts and outserts. As ... & Serialization Device. This addition will enable Flottman to individually code professional ...
(Date:12/9/2016)... , ... December 09, 2016 , ... The Justin ... Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and its ... District of Columbia as an education tool in the war against teen drug abuse. ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a ... , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is ... in a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I had ... an inventor from Winchester, Va. "I thought that if the nebulizer had a more ... rather than fearing them." , He developed the patent-pending NEBY to avoid the need ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
Breaking Medicine Technology: